IQV VS HLN Stock Comparison

Performance

IQV
91/100

IQV returned -8.00% in the last 12 months. Based on SPY's performance of -13.62%, its performance is above average giving it a score of 91 of 100.

HLN
100/100

HLN returned 20.18% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

IQV
69/100

17 analysts offer 12-month price targets for IQV. Together, they have an average target of 277.18, the most optimistic target put IQV at 320 within 12-months and the most pessimistic has IQV at 235.

HLN

"Analyst Price Targets" not found for HLN

Technicals

IQV
75/100

IQV receives a 75 of 100 based on 14 indicators. 10 are bullish, 3 are bearish.

HLN
50/100

HLN receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

IQV
100/100

IQV has missed earnings 0 times in the last 20 quarters.

HLN
100/100

HLN has missed earnings 1 times in the last 20 quarters.

Profit

IQV
88/100

Out of the last 20 quarters, IQV has had 19 profitable quarters and has increased their profits year over year on 12 of them.

HLN
72/100

Out of the last 9 quarters, HLN has had 9 profitable quarters and has increased their profits year over year on 3 of them.

Volatility

IQV
49/100

IQV has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.

HLN
57/100

HLN has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

All score calculations are broken down here to help you make more informed investing decisions

IQVIA Holdings Inc. Summary

New York Stock Exchange / IQV

Healthcare

Medical - Diagnostics & Research

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

Haleon plc American Depositary Shares (Each representing two Ordinary Shares) Summary

New York Stock Exchange / HLN

Healthcare

Drug Manufacturers - Specialty & Generic

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Power up your portfolio